Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 20, 2017JAMA OncologyOpen Access

HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma

View Full Paper
Ask AI
Bookmark
Share

Authors

NANabil AhmedHouston MethodistVBVita S. BrawleyHouston MethodistMHMeenakshi HegdeHouston Methodist

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ahmed et al. (2017) studied this question.

synapsesocial.com/papers/69db25b01e19c8ae08836c27https://doi.org/10.1001/jamaoncol.2017.0184
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group2011 · 404 citations
  2. 2Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma2015 · 1,266 citations
  3. 3Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma2015 · 774 citations
  4. 4EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss2013 · 298 citations
  5. 5Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation2013 · 555 citations